FWM
EDIT icon

Filbrandt Wealth Management’s Editas Medicine EDIT Stock Holding History

Filbrandt Wealth Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-25
Closed – – 393
2020
Q1 		$0 Buy
+25
New +$631 ﹤0.01% 271

Other funds holding EDIT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Filbrandt Wealth Management's EDIT Position: Q2 2020 in Review

Filbrandt Wealth Management sold out of Editas Medicine (EDIT) in Q2 2020, closing a stake of 25 shares.

Filbrandt Wealth Management first reported a position in EDIT in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 238 funds tracked by Wall St. Rank hold EDIT as of Q2 2020.

  • Filbrandt Wealth Management reported no remaining Editas Medicine position as of Q2 2020 after selling out during the quarter.
  • Filbrandt Wealth Management sold 25 Editas Medicine shares in Q2 2020.
  • Filbrandt Wealth Management first reported a position in Editas Medicine in Q1 2020 and held it in 1 quarter.
  • Filbrandt Wealth Management's Editas Medicine position peaked at $0 in Q1 2020.
  • 238 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2020.

Based on Filbrandt Wealth Management's 13F filing for Q2 2020, filed 11 Aug 2020.